Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: A retrospective pilot study

Acta Ophthalmologica

Volumn 86, Issue 5, 2008, Pages 490-494

  Meyer, Carsten H ^a   Scholl, Hendrik P ^a   Eter, Nicole ^a   Helb, Hans Martin ^a   Holz, Frank G ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Bevacizumab; Choroidal neovascularization; Expansile gas; Intravitreal injection recombined tissue plasminogen activator; Subretinal haemorrhages

Indexed keywords

ALTEPLASE; BEVACIZUMAB; SULFUR HEXAFLUORIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; MALE; PARACENTESIS; PILOT STUDY; PRIORITY JOURNAL; RANK SUM TEST; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINA HEMORRHAGE; VISUAL ACUITY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; COMBINED MODALITY THERAPY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PILOT PROJECTS; PRONE POSITION; RETINAL HEMORRHAGE; RETROSPECTIVE STUDIES; SULFUR HEXAFLUORIDE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 48449094548     PISSN: 1755375X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2007.01125.x     Document Type: Article

References (22)

1. Avery RI, Fekrat S, Hawkins BS & Bressler NM (1996): Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 16: 183-189.
2. Bartz-Schmidt KU & Holz FG (2006): Introduction to the topic: off-label use of bevacizumab in the treatment of neovascular age-related macular degeneration. Ophthalmologe 103: 461-462.
3. Bressler NM, Bressler SB, Childs AL, Haller JA, Hawkins BS, Lewis H, MacCumber MW, Marsh MJ, Redford M, Sternberg P Jr, Thomas MA, Williams GA; Submacular Surgery Trials (SST) Research Group (2004): Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Ophthalmic findings: SST report no. 13. Ophthalmology 111: 1993-2006.
4. Dwinger MC, Pieper-Bodeewes I, Eter N & Holz FG (2005): Variations in intraocular pressure (IOP) and necessity for paracentesis following intravitreal triamcinolone injection. Klin Monatsbl Augenheilkd 222: 638-642.
5. Glatt H & Machemer R (1982): Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 94: 762-773.
6. Hasler PW, la Cour M & Villumsen J (2007): Pneumatic displacement and intravitreal bevacizumab in the management of subretinal haemorrhage caused by choroidal neovascularization. Acta Ophthalmol Scand 85: 577-578.
7. Heriot W (1996): IntrAvitreal gas and rtPA: an outpatient procedure for subretinal hemorrhage. In: Vail Vitrectomy Meeting 1996: Vail Co.
8. Jaissle GB, Szurman P, Bartz-Schmidt KU; German Retina Society; German Society of Ophthalmology & German Professional Association of Ophthalmologists (2005): Recommendation for the implementation of intravitreal injections - statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists. Klin Monatsbl Augenheilkd 222: 390-395.
9. Kernt M, Neubauer AS & Kampik A (2007): Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 85: 119-120.
10. Kroll P & Meyer CH (2006): Which treatment is best for which AMD patient? Br J Ophthalmol 90: 128-130.
11. Ladewig MS, Ziemssen F, Jaissle G, Helb HM, Scholl HP, Eter N, Bartz-Schmidt KU & Holz FG (2006): Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmologe 103: 463-470.
12. Lincoff H & Kreissig I (2001): Intravitreal injection of tissue plasminogen activator and gas in subretinal hemorrhage caused by age-related macular degeneration. Retina 21: 191.
13. Luke M, Januschowski K, Warga M et al. (2007): The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol 91: 1077-1182.
14. Niemeyer M, Hefner L, Jochmann C & Wiedemann P (2007): Intravitreal Bevacizumab for recurring choroidal neovascularisation. Ophthalmologe 104: 158-160.
15. Rodrigues EB, Meyer CH, Grumann A, Shiroma H, Aguni JS & Farah ME (2007): Tunneled scleral incision for intravitreal injections. Am J Ophthalmol 143: 1035-1037.
16. Schmidt JC, Meyer CH & Hörle S (2004): Massive subretinal hemorrhages. A challenge for vitreous body surgeons. Ophthalmologe 101: 584-588.
17. Schulze SD & Hesse L (2002): Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: Predictive variables for visual outcome. Graefes Arch Clin Exp Ophthalmol 240: 717-720.
18. Scupola A, Coscas G, Soubrane G & Balestrazzi E (1999): Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica 213: 97-102.
19. Soliman W, Lund-Andersen H & Larsen M (2006): Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization. Acta Ophthalmol Scand 84: 707-708.
20. Spaide RF, Laud K, Fine HF et.al. (2006): Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26: 383-390.
21. Thomas MA, Williams DF & Grand MG (1992): Surgical removal of submacular hemorrhage and subfoveal choroidal neovascular membranes. Int Ophthalmol Clin 32: 173-188.
22. Yoganathan P, Deramo VA, Lai JC, Tibrewala RK & Fastenberg DM (2006): Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina 26: 994-998.